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TaiwanBackground: This study aimed to identify the efficacy and toxicity of bevacizumab plus FOLFIRI with irinotecan dose
escalation as first-line chemotherapy for metastatic colorectal cancer (mCRC) via prospective UGT1A1 genotyping.
Materials and Methods: We administered bevacizumab plus FOLFIRI with irinotecan dose escalation to treat 70 mCRC
patients, stratified according to UGT1A1 genotype. The clinical response rate, toxicity, and survival were analyzed.
Results: The clinical response and disease control rates of mCRC patients treated with FOLFIRI plus bevacizumab were
significantly better in patients with UGT1A1 6/6 and 6/7 genotypes than in patients with UGT1A1 7/7 (P Z 0.016 and
P < 0.005, respectively). Grade 3/4 adverse events were significantly more common in mCRC patients with the UGT1A1 7/72214-0247/$36 Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. All rights reserved.
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130 Abstractgenotype (P < 0.005). An irinotecan dose of >180 mg/m2 conferred a significantly higher therapeutic response than a dose
of <180 mg/m2 (PZ 0.024). Progression-free survival was significantly higher in UGT1A1 6/6 and 6/7 patients (P < 0.005).
mCRC patients who underwent metastasectomy achieved better overall survival than those who did not undergo meta-
stasectomy (P Z 0.015).
Conclusion: Our study showed that mCRC patients with UGT1A1 6/6 and 6/7 genotypes could receive escalated doses of
irinotecan to obtain a more favorable clinical outcome.
